免疫治疗在未分化甲状腺癌初始治疗中的总生存评估:基于国家癌症数据库的研究
该回顾性研究基于美国国家癌症数据库(2008-2020)3318例未分化甲状腺癌(ATC)患者,比较接受与未接受免疫治疗(IT)者的总生存(OS)。IT组87例(2.6%),中位OS为9.1个月 vs 3.78个月(p<0.005),5年OS为18% vs 9%(p<0.0001);但回顾性设计及缺乏IT药物细节等混杂因素限制结论。
要点
- ATC患者中仅2.6%接受免疫治疗,接受者更年轻且更多接受化疗。
- 免疫治疗与中位OS延长相关(9.1 vs 3.78个月),但为回顾性关联。
- 接受手术+免疫+放疗三联治疗的23例患者5年OS达35%。
核心结论
- 免疫治疗与ATC患者总生存延长相关,但回顾性设计等混杂因素使无法确定其疗效。
- 免疫治疗作为ATC单独治疗的疗效尚不明确。
研究设计与样本
- 回顾性研究,数据来自美国国家癌症数据库(2008-2020),纳入3318例转移性和非转移性ATC患者。
- 患者接受手术、放疗、化疗或联合治疗,按治疗期间是否接受免疫治疗分层比较OS。
主要发现
- 3318例ATC患者中87例(2.6%)接受免疫治疗。
- 免疫治疗组中位OS为9.1个月(CI 7.06-14.9),未接受组为3.78个月(CI 3.52-4.01),p<0.005。
- 免疫治疗组5年OS为18%(CI 5-36%),未接受组为9%(CI 8-10%),p<0.0001。
- 接受手术、免疫治疗和放疗三联治疗的23例患者5年OS为35%(CI 16-55%),未接受者为9%。
- 免疫治疗组患者更年轻(平均66.7 vs 70.2岁,p=0.005),更多在2017-2019年诊断(p=0.0001),更常接受化疗(65.5% vs 46.3%,p=0.0007)。
临床怎么用
- 免疫治疗可能作为ATC初始治疗的选择之一,尤其在与手术和放疗联合时需个体化评估。
- 临床决策时应考虑患者年龄、诊断年份和化疗联合情况等混杂因素。
局限性
- 回顾性研究设计存在混杂因素。
- 缺乏免疫治疗药物细节和治疗顺序信息。
- 无法确定免疫治疗作为单独治疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid cancer (ATC) is an aggressive malignancy with a median survival of six months. While immunotherapy (IT) has improved outcomes in other solid tumors, its role in ATC remains unclear. This study evaluated whether receipt of IT was associated with improved overall survival (OS) in the initial treatment of patients with newly diagnosed ATC. Methods: We performed a retrospective study of patients with metastatic and nonmetastatic ATC from the National Cancer Database (2008-2020) treated with surgery, radiation, chemotherapy, or a combination. Patient outcomes were stratified between those who received IT at any point in their treatment compared with those who did not. The primary outcome was OS, compared between cohorts receiving IT and those who did not. Survival analyses were performed using Kaplan-Meier estimates, long-rank tests, and multivariable models. Results: Among 3318 patients with ATC, 87 (2.6%) received IT. Rates of surgical resection (46%) and radiation therapy (64% vs. 57%, p = 0.133) were similar across groups. IT recipients were younger (mean = 66.7 vs. 70.2 years, p = 0.005), more often diagnosed in recent years (2017-2019 vs. 2008-2016, p = 0.0001), and more frequently received chemotherapy (65.5% vs. 46.3%, p = 0.0007). Charlson Comorbidity Index scores were similar (p = 0.551). Median OS was 9.1 months (confidence interval [CI] 7.06-14.9) for those receiving IT versus 3.78 months (CI: 3.52-4.01) for those who did not (p < 0.005). Five-year OS was 18% (CI: 5-36%) with IT versus 9% (CI: 8-10%) without (p < 0.0001). Among 23 patients who received trimodality therapy (surgery, IT, and radiation), 5-year OS was 35% (CI: 16-55%) versus 9% in patients who did not. Conclusions: IT was associated with prolonged survival in patients with ATC, although confounding factors, such as the retrospective design of the study, lack of detailed IT drug details, and sequencing of therapy, preclude definitive conclusions on its efficacy. The efficacy of IT for ATC as a stand-alone treatment is uncertain. Further studies could indicate which combination of therapies best increases OS in patients with ATC.
引用
- Kini S, Yildiz V, Mitchell D, et al. Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study. Thyroid. 2025. PMID: 40897520. doi:10.1177/10507256251372191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。